User:C Michael Gibson

Revision as of 18:46, 15 October 2009 by C Michael Gibson (talk | contribs)
Jump to navigation Jump to search
WikiDoc Founder C. Michael Gibson, M.S., M.D.
WikiDoc Founder C. Michael Gibson, M.S., M.D.

C. Michael Gibson M.S., M.D., Associate Professor of Medicine, Harvard Medical School

Founder and Chairman of the Board, WikiDoc Foundation (a 509 (a)(1) Charitable Organization)

Contact: mailto:mgibson@wikidoc.org; Phone 617-632-7753

Address: C. Michael Gibson, M.S., M.D., 350 Longwood Avenue, First Floor, Boston MA, 02115.

Click heremedia:C michael gibson large.tifto download a large image (tif) or here to download a small headshot


Dr. Gibson received his B.S., M.S., and M.D. degrees from the University of Chicago. He was an Intern, Resident and Chief Resident at the Brigham and Women’s Hospital, Harvard Medical School. He received his training as an interventional cardiologist and served as the Director of the Coronary Care Unit at Beth Israel Hospital, Harvard Medical School. Dr. Gibson then served as the Chief of Cardiology and Director of Interventional Cardiology at the West Roxbury Veterans Affairs Medical Center, Harvard Medical School. While at the West Roxbury VA, he also served as an Associate Physician at the Brigham and Women’s Hospital. He then moved on to Allegheny General Hospital as Vice Chairman of Medicine for Clinical Research and Director of Invasive Cardiology. He subsequently relocated to the west coast and served as Associate Chief of Cardiology, Chief of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory at University of California San Francisco (UCSF). In 2000, Gibson returned to Harvard Medical School in Boston. Until 2003, Dr. Gibson served as Chief Academic Officer and Director of Core Services at Harvard Clinical Research Institute (HCRI), until 2005 he served as Associate Chief of Cardiology and Director of Academic Affairs in the Cardiovascular Division at the Beth Israel Deaconess Medical Center. Until 2009 he served as the Director of the TIMI Data Coordinating Center at the Brigham and Women’s Hospital. He is currently a full time interventional cardiologist and Chief of Clinical Research in the Cardiovascular Division at Beth Israel Deaconess Medical Center, Harvard Medical School.


Dr. Gibson’s work has largely focused on investigating the pathophysiology of coronary artery disease and the efficacy of pharmacologic and device based therapies. His work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters.


Over 20 years ago, Gibson founded PERFUSE, an academic research organization which has served as the angiographic core laboratory and data coordinating center for a wide variety of studies including acute MI studies, unstable angina studies, interventional cardiology trials, peripheral interventional trials, venographic trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). Gibson directed the TIMI angiographic core laboratory and invented the TIMI frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted (an index of epicardial blood flow). Gibson also invented the TIMI myocardial perfusion grade (the blush, a measure of microvascular perfusion). The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of 2 year mortality in acute MI, and are now widely used both clinically and in the assessment of new reperfusion strategies. The methods invented by Gibson and his reasearch have played a critical role in our understanding of "the open artery hypothesis" and more recently in what Gibson has termed "the open muscle hypothesis". On Google scholar, the TIMI Frame Count is listed as being cited in about 2,000 articles (for updated numbers click here)


Under Gibson's direction, PERFUSE created the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center.


Within the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Dr. Gibson has served as a Principle Investigator of multiple international trials within the TIMI Study Chairman’s Office.


Dr. Gibson is Founder and Chairman of the Board of WikiDoc Foundation (a 509 (a)(1) Charitable Organization). This is the world's largest medical textbook / encyclopedia. There are currently over 30,000 page views daily of over 75,000 chapters of content contributed and edited over 400,000 times by over 1,200 registered users.


Dr. Gibson also edited a textbook entitled “Management Strategies in Interventional Cardiology” which is optimized for hand held devices. In the past, Gibson has authored the chapter on Primary Angioplasty in Randomized Trials in Cardiovascular Disease published as a companion to Braunwald's Heart Disease. In the past he has co-authored the chapter “Recognition and Management of Patients with Stable Angina Pectoris in Braunwald and Goldman’s Primary Cardiology. He has served as lead author of the section on myocardial perfusion imaging in a imaging textbook which is a companion to Braunwald’s Heart Disease.


Dr. Gibson is on the editorial board of Circulation. Dr. Gibson is Editor-in-Chief of Clinical Trial Results where he created the first weekly TV show for Cardiologists "This Week in Cardiology". Gibson also created TIMI.org, the website of the TIMI Study Group.


Dr. Gibson lectures internationally on the topics of interventional cardiology, antithrombotics, antiplatelet agents, acute coronary syndromes, atherosclerosis and lipid-lowering, the future of medical communication and the concept of "copyleft" as well as pay for performance.


In 2007, Gibson was selected by Who's Who as the Clinical Researcher of the Year.

Disclosures:

Present Research/Grant Funding

Abbott; Angel Medical Corporation; Astra Zeneca; Atrium Medical Systems; Baxter; Bayer Corp. Cardica, Inc.; FibroGen, Inc.; Fold Rx; Genentech, Inc.; HeartScape Technologies; INO Therapeutics, Inc.; Johnson & Johnson Corporation; Lantheus Medical Imaging; NewCardio, Inc.; Portola Pharmaceuticals; Sanofi-Aventis; Schering Plough Corporation


Speakers Bureau

Daiichi Sankyo Company, Inc; Eli Lilly and Company; Glaxo SmithKline; Schering Plough Corporation; The Medicines Company


Consultant

Acusphere, Inc.; Angel Medical Systems; Archemix Corporation; Ascenta Therapeutics Atrium Medical Corporation; Bayer Corporation; Cardica Inc.; Heartscape Technologies, Inc.; ICON Medical Imaging; Jim Moran Heart and Vascular Research Institute; John & Johnson Corporation; Medicure, Inc.; Novartis Pharmaceutical Corporation; Portola Pharmaceuticals, Inc.; Sanofi-Aventis Pharmaceuticals; Schering Plough Corporation; St. Jude Medical; The Medicines Company


Stock Ownership

My wife owns stock in HealthMarx Inc.


Royalties as a Contributor

UpToDate in Cardiovascular Medicine; Pocket Medicine


Past Research/Grant Funding/Past Speakers Bureau/Past Consulting

ActivBiotics, Inc.; Acusphere, Inc.; Ascenta Therapeutics, Inc; Astra; Atrium Medical Corporation; Bard Corporation; Biogen IDEC; Boston Scientific Corporation; Bristol Meyers Squibb Company; British Biotech, plc.; CardioKinetix, Inc.; Ciba Geigy Corporation; COR Therapeutics; Corgentech, Inc.; DVI Guidant Corporation; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; INO Therapeutics, LLC; KAI Pharmaceuticals; Merck & Co., Inc.; Millennium Pharmaceuticals; Momenta Pharmaceuticals; NIH; Novartis Corporation; Nuvelo; PDL Pharmaceuticals; Percusurge, Inc.; Pfizer; Point Biomedical Corporation; Portola Pharmaceuticals, Inc.; Sanofi-Aventis Corporation; Smith Kline Beecham; Sonus; St. Jude Medical; The Medicines Company; timi3 Systems, Inc.